{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:04:24Z","timestamp":1790186664888,"version":"4.1.0"},"reference-count":21,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2016,12,14]]},"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Sodium glucose cotransporter 2 (SGLT2) inhibitors are effective blood-glucose-lowering medications with beneficial effects on body weight in patients with type 2 diabetes mellitus (T2DM). However, observed weight loss is less than that predicted from quantified glycosuria, suggesting a compensatory increase in energy intake or a decrease in energy expenditure. Studies using dual-energy X-ray absorptiometry (DEXA) have suggested most body weight change is due to loss of adipose tissue, but organ-specific changes in fat content (eg, liver, skeletal muscle) have not been determined. In this randomised, double-blind, placebo-controlled crossover study, we aim to study the compensatory changes in energy intake, eating behaviour and energy expenditure accompanying use of the SGLT2 inhibitor, dapagliflozin. Additionally, we aim to quantify changes in fat distribution using MRI, in liver fat using proton magnetic resonance spectroscopy (\n                      <jats:sup>1<\/jats:sup>\n                      H-MRS) and in central nervous system (CNS) responses to food images using blood oxygen level dependent (BOLD) functional MRI (fMRI).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This outpatient study will evaluate the effect of dapagliflozin (10\u2005mg), compared with placebo, on food intake and energy expenditure at 7\u2005days and 12\u2005weeks. 52 patients with T2DM will be randomised to dapagliflozin or placebo for short-term and long-term trial interventions in a within participants, crossover design. The primary outcome is the difference in energy intake during a test meal between dapagliflozin and placebo. Intake data are collected automatically using a customised programme operating a universal eating monitor (UEM). Secondary outcomes include (1) measures of appetite regulation including rate of eating, satiety quotient, appetite ratings (between and within meals), changes in CNS responses to food images measured using BOLD-fMRI, (2) measures of energy expenditure and (3) changes in body composition including changes in liver fat and abdominal visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethical approval<\/jats:title>\n                    <jats:p>This study has been approved by the North West Liverpool Central Research Ethics Committee (14\/NW\/0340) and is conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice (GCP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.isrctn.com\/ISRCTN14818531\" ext-link-type=\"uri\">ISRCTN14818531<\/jats:ext-link>\n                      . EUDRACT number 2013-004264-60.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2016-013539","type":"journal-article","created":{"date-parts":[[2017,1,28]],"date-time":"2017-01-28T20:10:31Z","timestamp":1485634231000},"page":"e013539","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)\u2014study protocol"],"prefix":"10.1136","volume":"7","author":[{"given":"Surya Panicker","family":"Rajeev","sequence":"first","affiliation":[{"name":"Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK"},{"name":"Diabetes and Endocrinology Research Group, Clinical Sciences Centre, Aintree University Hospital NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria S","family":"Sprung","sequence":"additional","affiliation":[{"name":"Diabetes and Endocrinology Research Group, Clinical Sciences Centre, Aintree University Hospital NHS Foundation Trust, Liverpool, UK"},{"name":"Department of Musculoskeletal Biology II, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Psychological Sciences, Institute of Psychology, Health and Society, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo A","family":"Harrold","sequence":"additional","affiliation":[{"name":"Department of Psychological Sciences, Institute of Psychology, Health and Society, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason C G","family":"Halford","sequence":"additional","affiliation":[{"name":"Department of Psychological Sciences, Institute of Psychology, Health and Society, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Stancak","sequence":"additional","affiliation":[{"name":"Department of Psychological Sciences, Institute of Psychology, Health and Society, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma J","family":"Boyland","sequence":"additional","affiliation":[{"name":"Department of Psychological Sciences, Institute of Psychology, Health and Society, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham J","family":"Kemp","sequence":"additional","affiliation":[{"name":"Department of Musculoskeletal Biology II, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK"},{"name":"Magnetic Resonance and Image Analysis Research Centre (MARIARC), University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J","family":"Cuthbertson","sequence":"additional","affiliation":[{"name":"Diabetes and Endocrinology Research Group, Clinical Sciences Centre, Aintree University Hospital NHS Foundation Trust, Liverpool, UK"},{"name":"Department of Musculoskeletal Biology II, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P H","family":"Wilding","sequence":"additional","affiliation":[{"name":"Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK"},{"name":"Diabetes and Endocrinology Research Group, Clinical Sciences Centre, Aintree University Hospital NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,1,27]]},"reference":[{"key":"2025121410573163000_7.1.e013539.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2013.11.002"},{"key":"2025121410573163000_7.1.e013539.2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112981"},{"key":"2025121410573163000_7.1.e013539.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60407-2"},{"key":"2025121410573163000_7.1.e013539.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01659.x"},{"key":"2025121410573163000_7.1.e013539.5","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0606"},{"key":"2025121410573163000_7.1.e013539.6","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-6-201203200-00003"},{"key":"2025121410573163000_7.1.e013539.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60812-X"},{"key":"2025121410573163000_7.1.e013539.8","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2012.59"},{"key":"2025121410573163000_7.1.e013539.9","doi-asserted-by":"publisher","DOI":"10.2337\/db15-1356"},{"key":"2025121410573163000_7.1.e013539.10","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12578"},{"key":"2025121410573163000_7.1.e013539.11","doi-asserted-by":"crossref","unstructured":"Cuthbertson DJ , Irwin A , Gardner CJ , et al . Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One 2012;7. doi:10.1371\/journal.pone.0050117","DOI":"10.1371\/journal.pone.0050117"},{"key":"2025121410573163000_7.1.e013539.12","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108095195"},{"key":"2025121410573163000_7.1.e013539.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-7634(99)00078-0"},{"key":"2025121410573163000_7.1.e013539.14","first-page":"R764","article-title":"Energy metabolism rate equation for fasting and postabsorptive subjects","volume":"244","author":"Ben-Porat","year":"1983","journal-title":"Am J Physiol"},{"issue":"(6 Pt 2)","key":"2025121410573163000_7.1.e013539.15","first-page":"R1347","article-title":"Reappraisal of the Weir equation for calculation of metabolic rate","volume":"258","author":"Mansell","year":"1990","journal-title":"Am J Physiol"},{"key":"2025121410573163000_7.1.e013539.16","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/ijo.2015.82","article-title":"Cerebral activations during viewing of food stimuli in adult patients with acquired structural hypothalamic damage: a functional neuroimaging study","volume":"39","author":"Steele","year":"2015","journal-title":"Int J Obes (Lond)"},{"key":"2025121410573163000_7.1.e013539.17","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.036566"},{"key":"2025121410573163000_7.1.e013539.18","first-page":"E977","article-title":"Measurement of intracellular triglyceride stores by H-1 spectroscopy: validation in vivo","volume":"276","author":"Szczepaniak","year":"1999","journal-title":"Am J Physiol"},{"key":"2025121410573163000_7.1.e013539.19","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780131703"},{"key":"2025121410573163000_7.1.e013539.20","doi-asserted-by":"publisher","DOI":"10.1177\/096228029400300402"},{"key":"2025121410573163000_7.1.e013539.21","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0195-6663(82)80022-6","article-title":"A quadratic equation adequately describes the cumulative food intake curve in man","volume":"3","author":"Kissileff","year":"1982","journal-title":"Appetite"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2016-013539","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T18:57:38Z","timestamp":1765738658000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2016-013539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1,27]]},"published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1136\/bmjopen-2016-013539"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2016-013539","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}